Learn more about an open-label study evaluating an investigational, once-nightly narcolepsy medication

The RESTORE study is currently enrolling participants.

Building on the recently completed REST-ON clinical trial, RESTORE is an open-label study evaluating FT218, an investigational sodium oxybate medicine for the once-nightly treatment of excessive daytime sleepiness and cataplexy due to narcolepsy. All participants in the RESTORE study will receive the investigational medication at no cost.

The open-label study is designed to assess the long-term safety and tolerability of FT218 in patients with narcolepsy. You should also know:

- To be eligible for participation, patients must be 16 years of age or older with a diagnosis of narcolepsy with or without cataplexy
- Participants must be on a stable dose of twice-nightly sodium oxybate (for at least 4 weeks) OR have completed the REST-ON trial of FT218
- Your study-related medical expenses will be covered

By enrolling in the RESTORE open-label study, you have the opportunity to help evaluate a new potential treatment option.

To find a study site near you, please visit www.restore-narcolepsy-study.com/study-locations.